

SEQUENCE LISTING

<110> Ferrer Internacional, S.A.

<120> OPHTHALMIC PHARMACEUTICAL COMPOSITION AND USE THEREOF

<130> P5687PC00

<150> EP20382101.2

<151> 2020-02-13

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 13

<212> PRT

<213> Artificial

<220>

<223> N-terminal region of a peptide able to interact with the mammal glucagon-like peptide-1 receptor

<220>

<221> VARIANT

<222> (2)..(2)

<223> X is an amino acid selected from alanine and glycine

<220>

<221> VARIANT

<222> (10)..(10)

<223> X is an amino acid selected from valine and leucine

<220>

<221> VARIANT

<222> (12)..(12)

<223> X is an amino acid selected from serine and lysine

<220>

<221> VARIANT

<222> (13)..(13)

<223> X is an amino acid selected from tyrosine and glutamine

<400> 1

His Xaa Glu Gly Thr Phe Thr Ser Asp Xaa Ser Xaa Xaa

1

5

10

<210> 2

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<220>

<221> MOD_RES

<222> (30)..(30)

<223> AMIDATION

<400> 2

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg
			20					25					30

<210> 3

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 3

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg	Gly
			20					25					30	

<210> 4

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide

<400> 4

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr
1				5					10			